Reversal of atherosclerosis with apolipoprotein A1: Back to basics

Atherosclerosis

Volumn 232, Issue 1, 2014, Pages 217-219

  Smits, Loek P ^a   Kootte, Ruud S ^a   Stroes, Erik S ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Apolipoprotein A 1 (apoA 1); Atherosclerosis; Cardiovascular disease (CVD); High density lipoprotein (HDL); Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; CER 001; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL TRANSPORT; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; NONHUMAN; NOTE; PRIORITY JOURNAL;

APOLIPOPROTEIN A-1 (APOA-1); ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE (CVD); HIGH-DENSITY LIPOPROTEIN (HDL); REVERSE CHOLESTEROL TRANSPORT;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOMIMETICS; HUMANS; LIPOPROTEINS, HDL; MALE; PHOSPHOLIPIDS; RECOMBINANT PROTEINS;

EID: 84891616741     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.08.010     Document Type: Note

References (27)

1. Baigent C., Keech A., Kearney P., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
2. Takaya N., Yuan C., Chu B., et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI-initial results. Stroke: A Journal of Cerebral Circulation 2006, 37:818-823.
3. Vergeer M., Holleboom A.G., Kastelein J.J.P., Kuivenhoven J.A. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosisα. Journal of Lipid Research 2010, 51:2058-2073.
4. Van der Steeg W.A., Holme I., Boekholdt S., et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. Journal of the American College of Cardiology 2008, 51:634-642.
5. Van Capelleveen J.C., Bochem A.E., Motazacker M.M., Hovingh G.K., Kastelein J.J.P. Genetics of HDL-C: a causal link to atherosclerosisα. Current Atherosclerosis Reports 2013, 15:326.
6. Voight B.F., Peloso G., Ortho-Melander M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012, 380:572-580.
7. Brousseau M.E., Diffenderfer M., Millar J., et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25:1057-1064.
8. Holleboom A.G., Jakulj L., Franssen R., et al. Invivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. Journal of Lipid Research 2013, 54:1964-1971.
9. Briel M., Ferreira-Gonzalez I., You J., et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ (Clinical Research Ed.) 2009, 338(b92).
10. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. The New England Journal of Medicine 2007, 357:2109-2122.
11. Schwartz G.G., Olsson A., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. The New England Journal of Medicine 2012, 367:2089-2099.
12. Boden W.E., Probstfield J., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. The New England Journal of Medicine 2011, 365:2255-2267.
13. Presentation American College of Cardiology meeting March 9 2013 Slideshow. Available from:. http://www.thrivestudy.org.
14. Tardy C., Goffinet M., Boubekeur N., et al. CER-001, an HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis 2014, 232:110-118.
15. Zhang Y., Zanotti I., Reilly M., et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces invivo. Circulation 2003, 108:661-663.
16. Mackey R.H., Greenland P., Goff D., et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). Journal of the American College of Cardiology 2012, 60:508-516.
17. Tardif J.-C., Grégoire J., L'Allier P., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA: The Journal of the American Medical Association 2007, 297:1675-1682.
18. Nissen S.E., Tsunoda T., Tuzcu E., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA: The Journal of the American Medical Association 2003, 290:2292-2300.
19. Eriksson M., Carlson L.A., Miettinen T.A., Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein a-I: potential reverse cholesterol transport in humans. Circulation 1999, 100:594-598.
20. Nanjee M.N., Cooke C., Garvin R., et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. Journal of Lipid Research 2001, 42:1586-1593.
21. Rader D.J., Alexander E.T., Weibel G.L., Billheimer J., Rothblat G.H. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. Journal of Lipid Research 2009, 50(Suppl):S189-S194.
22. Nissen S.E. Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. The American Journal of Cardiology 2002, 89:24B-31B.
23. Balu N., Wang J., Dong L., et al. Current techniques for MR imaging of atherosclerosis. Topics in Magnetic Resonance Imaging: TMRI 2009, 20:203-215.
24. Di Bartolo B.A., Nicholls S., Bao S., et al. The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis 2011, 217:395-400.
25. Sarov-Blat L., Kiss R., Haidar B., et al. Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:1115-1122.
26. Birjmohun R.S., van Leuven S., Levels J., et al. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. Arteriosclerosis, Thrombosis, and Vascular Biology 2007, 27:1153-1158.
27. Feig J.E., Parathath S., Rong J., et al. Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 2011, 123:989-998.